Metabolism Supplement Guide: What The Evidence Shows

Start with the two numbers that frame everything below. a review of 315 weight-loss supplement trials reviewed 315 randomised trials of weight-loss supplements and found 52 of them low-risk and adequately powered. Of those 52, sixteen reported a weight difference against placebo. That is the base rate a reader should carry into any claim in this aisle.

a meta-analysis of isolated compounds did the other half of the job, pooling trials of the isolated compounds rather than the finished products, and found that none of them met a 2.5 kg threshold for clinical significance. The compounds are not doing nothing; they are doing something small enough that a trial has to be careful to see it.

a network meta-analysis of 111 nutraceutical trials ran a network analysis across 111 nutraceutical trials and reached a similar place from a different direction, and a comparison of thermogenics with diet and exercise is the comparison worth keeping in view: a thermogenic supplement set against diet and exercise, where the latter is not a close contest.

There is a safety side to it. the NEJM emergency-department study found weight-loss products over-represented among supplement-related emergency visits, mostly through cardiac symptoms in young adults; a 2017 review of supplement-related liver injury and a review of adverse events in this category cover the liver and adverse-event literature.

Dulloo's 100 mg thermogenesis study is the trial everything else in this category is measured against. Lean and post-obese volunteers were given 100 mg of caffeine and their resting metabolic rate rose three to four per cent over the following 150 minutes. Repeated two-hourly across a day it moved daily energy expenditure by 150 kcal in the lean group and 79 kcal in the post-obese one.

Astrup's dose-response trial ran 100, 200 and 400 mg and found the thermogenic response dose-dependent, which is the finding that makes a printed caffeine figure worth reading rather than skipping. a 2022 cycling trial is a more recent demonstration in a performance setting.

Two things follow for a buyer. The first is that 150 kcal a day is roughly a banana and a half, which is a real number and a modest one, and any capsule promising a transformation from a caffeine row is overselling a well-measured small effect. The second is that caffeine is a single compound, so a milligram figure on a panel is a milligram of the substance the trials gave. That is not true of any botanical extract beside it.

The ceiling is well characterised. the systematic review behind the 400 mg figure is the systematic review behind the widely quoted 400 mg a day for healthy adults, and a comprehensive review of ingested caffeine is the broader review across age groups. a review of multi-ingredient caffeine supplements looks specifically at multi-ingredient products built around caffeine, which is what almost every product in this aisle is.

Nagao's 583 mg catechin trial is the trial usually cited: a beverage delivering 583 mg of catechins a day over twelve weeks, against a control at 96 mg, with a difference in body fat at the end. a high-dose EGCG trial went further, at 857 mg of EGCG a day.

the green tea and caffeine chamber study is the more interesting one for anybody reading a combination product. It ran green tea extract with caffeine in a respiratory chamber and found the combination raised 24-hour energy expenditure, while an equivalent amount of caffeine alone did not. a meta-analysis of catechins with caffeine pooled that pairing across trials.

a 2024 dose-response meta-analysis is the dose-response analysis, a 2024 meta-analysis of catechins with exercise looks at catechins alongside exercise, and a long-term supplementation trial is the longer-term supplementation picture, which is more modest than the short trials suggest.

The catch is arithmetic rather than evidence. Those figures are catechins or EGCG, and a label almost always prints extract. An extract is some percentage catechin by weight, and unless that percentage is on the panel there is no way to convert one number into the other. A 250 mg extract row might carry 125 mg of catechins or it might carry 45.

There is a safety literature here too and it is dose-related. a systematic review of green tea safety and the US Pharmacopeia safety review review it, the LiverTox chapter on green tea is the reference chapter, the DILIN green tea study identifies a genetic susceptibility, and the SLIMQUICK case series is the case series from a specific product. NCCIH on green tea is the plain-language summary.

the 1998 JAMA trial put 135 overweight adults on 1,500 mg of hydroxycitric acid a day for twelve weeks and found no advantage over placebo on body weight or fat mass. It was published in JAMA in 1998 and it remains the largest and most-cited trial of the ingredient.

That is not the whole file. a dose-response meta-analysis is a dose-response meta-analysis that reaches a more favourable conclusion, and it is cited here rather than omitted, because a guide that prints only the negative result is doing the mirror image of what a sales page does. a 2020 review of herbal weight-loss medicines reviews the herbal weight-loss category around it and a scientific overview of the plant is the botanical overview. a 2023 trial in women with fatty liver is a more recent trial in a specific population.

The same extract-versus-compound problem applies and is worse here, because hydroxycitric acid content varies widely between preparations. A label printing “garcinia cambogia extract, 500 mg” with no acid percentage has given a true number that cannot be compared with the 1,500 mg of acid the trial used.

The safety literature is the reason this ingredient gets named in liver chapters. the LiverTox chapter on Garcinia cambogia is the reference, the DILIN analysis of garcinia and green tea is the network analysis covering both garcinia and green tea, and a 2016 acute liver failure report, a transplant case series and a 2019 hepatotoxicity case report are the case reports. These are uncommon events against a very large number of exposures, and they are also the reason the ingredient is worth knowing about rather than shrugging at.

Kondo's twelve-week vinegar trial is the twelve-week Japanese trial behind almost every vinegar claim in this category. Participants drank 15 mL or 30 mL of vinegar daily, carrying roughly 750 mg and 1,500 mg of acetic acid respectively, and both groups showed modest reductions in body weight and visceral fat against placebo.

a 2025 meta-analysis of body composition is the 2025 meta-analysis of body composition and finds its effects at 30 mL a day. a meta-analysis of lipids and glucose covers lipids and glucose, a meta-analysis of postprandial glucose the postprandial glucose response specifically, and a dose-response analysis in type 2 diabetes the dose-response in type 2 diabetes.

The gap between that and a capsule is the whole issue. Vinegar powder on a panel is typically a spray-dried preparation on a carrier, and a 150 mg row cannot carry 750 mg of anything. Where the powder’s own acetic acid content is not printed, even that comparison is generous rather than precise.

There is a reason to prefer the capsule on one narrow point. a trial of tooth wear in vinegar drinkers measured tooth wear in people who drink vinegar regularly, and a review of apple vinegar's side effects reviews the oesophageal side of it. A powder in a shell avoids both. It also avoids the dose that produced the results.

Whiting's systematic review is the systematic review, a meta-analysis of red pepper and thermogenesis the meta-analysis of red pepper and thermogenesis, and a 2022 review of capsaicin and body weight the more recent review of capsaicin and body weight. Between them they land on an effect around 34 to 50 kcal a day, which is in the same territory as caffeine’s and, like caffeine’s, is real and small.

Every one of those figures is reported in capsaicinoid milligrams, because that is the compound doing the work. Labels overwhelmingly print milligrams of cayenne or of capsicum extract, which is a weight of plant material containing some unstated percentage of capsaicinoids.

So the honest position on a cayenne row with no capsaicinoid figure is that it cannot be compared with the research at all. It is not below the trial dose; it is measured in a different unit, and converting between them without the percentage would be inventing the number.

The alternative is a comparison that looks rigorous and is not: converting extract milligrams into an implied capsaicinoid figure adds a decimal point to a guess.

Shoba's bioavailability study gave human volunteers 20 mg of piperine alongside curcumin and measured a two-thousand per cent rise in curcumin bioavailability. That single result is why black pepper extract appears on so many panels, and it is a genuine and striking finding.

What it is not is a general absorption enhancer for everything. a review of curcumin-piperine studies reviews the curcumin-piperine work specifically, and a review of piperine's physiological effects covers piperine’s broader physiological effects. The evidence is ingredient-specific: a pepper extract sitting next to substances it has never been tested with is doing an unproven job.

It also has a consequence outside the bottle. the CYP3A inactivation study showed piperine inactivates CYP3A, the enzyme system that clears a long list of prescription medicines. Raising absorption is the point; raising the absorption of a medicine nobody intended to change is the risk, and it is worth naming to whoever wrote the prescription.

the DILIN assay of supplement contents is the reason the fourth habit matters more than it sounds. When researchers assayed supplements implicated in liver injury, the contents and the label did not always agree, and a label is still the best available document rather than a guaranteed one.

NCCIH's guidance on using supplements wisely and MedlinePlus on weight control are the plain-language versions of all of this.

“Supports metabolism” is a structure-function claim. It says a substance plays a role in a normal bodily process, it does not require FDA pre-approval, and it comes with the requirement that the FDA disclaimer appears alongside it.

“Causes weight loss” is a drug claim. It asserts an effect on a condition, and a product making it would need to be approved as a drug. That is why every compliant bottle in this aisle uses the first form of words and why a website selling one should not quietly upgrade it.

The practical test is simple. Where the front of a bottle promises a transformation and the back says the statements have not been evaluated, read the back.

The modest language on a compliant label is not modesty. It is the boundary of what may be said without a trial behind it.

None of that makes these ingredients pointless. It makes them small, which is a different thing, and it puts the burden on a label to be precise about amounts if it wants to be taken seriously.

A panel that prints an amount against every row is doing that. The seven checks turn this into something you can run on a bottle in a shop, and the ingredients page runs them on this one.